Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Nature Medicine

Volumn 17, Issue 7, 2011, Pages 875-882

  Johnson, Neil ^a,b   Li, Yu Chen ^a   Walton, Zandra E ^a   Cheng, Katherine A ^a   Li, Danan ^a   Rodig, Scott J ^a,b   Moreau, Lisa A ^a,c   Unitt, Christine ^a,b   Bronson, Roderick T ^a   Thomas, Huw D ^d   Newell, David R ^d   D'Andrea, Alan D ^a,c   Curtin, Nicola J ^d   Wong, Kwok Kin ^a,b,e   Shapiro, Geoffrey I ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AG 024322; AG 14361; AURORA B KINASE; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; RO 3306; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CANCER SURVIVAL; DNA REPAIR; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; BRCA1 PROTEIN; BREAST NEOPLASMS; CARRIER PROTEINS; CDC2 PROTEIN KINASE; CELL DEATH; CELL LINE, TUMOR; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDAZOLES; INDOLES; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES;

EID: 79960150694     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2377     Document Type: Article

References (36)

1. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770-1783 (2006). (Pubitemid 46628473)
2. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166 (2009).
3. Hochegger, H. et al. An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells. J. Cell Biol. 178, 257-268 (2007). (Pubitemid 47076462)
4. Ira, G. et al. DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature 431, 1011-1017 (2004). (Pubitemid 39434425)
5. Jazayeri, A. et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37-45 (2006). (Pubitemid 43064795)
6. Tian, B., Yang, Q. & Mao, Z. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat. Cell Biol. 11, 211-218 (2009).
7. Myers, J.S., Zhao, R., Xu, X., Ham, A.J. & Cortez, D. Cyclin-dependent kinase 2 dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage. Cancer Res. 67, 6685-6690 (2007). (Pubitemid 47105514)
8. Johnson, N. et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol. Cell 35, 327-339 (2009).
9. Moynahan, M.E., Chiu, J.W., Koller, B.H. & Jasin, M. Brca1 controls homology-directed DNA repair. Mol. Cell 4, 511-518 (1999). (Pubitemid 29531131)
10. Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). (Pubitemid 40559005)
11. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
12. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006). (Pubitemid 44299177)
13. Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790 (2008).
14. Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
15. Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244 (2010).
16. Audeh, M.W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251 (2010).
17. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (2004). (Pubitemid 39331153)
18. Bhattacharyya, A., Ear, U.S., Koller, B.H., Weichselbaum, R.R. & Bishop, D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899-23903 (2000). (Pubitemid 30624678)
19. Elstrodt, F. et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 66, 41-45 (2006). (Pubitemid 43166006)
20. Cai, D., Latham, V.M. Jr., Zhang, X. & Shapiro, G.I. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 66, 9270-9280 (2006). (Pubitemid 44521149)
21. Vassilev, L.T. et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. USA 103, 10660-10665 (2006). (Pubitemid 44078033)
22. Pierce, A.J., Johnson, R.D., Thompson, L.H. & Jasin, M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633-2638 (1999). (Pubitemid 29508550)
23. Brown, A.P. et al. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion. Cancer Chemother. Pharmacol. 62, 1091-1101 (2008).
24. Calabrese, C.R. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96, 56-67 (2004).
25. Thomas, H.D. et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 6, 945-956 (2007). (Pubitemid 46554564)
26. Plummer, R. et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923 (2008).
27. Hackett, A.J. et al. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J. Natl. Cancer Inst. 58, 1795-1806 (1977). (Pubitemid 8118760)
28. Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007). (Pubitemid 47266337)
29. Turner, N.C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368-1377 (2008). (Pubitemid 351655175)
30. Esashi, F. et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434, 598-604 (2005). (Pubitemid 40488546)
31. Jackson, E.L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005). (Pubitemid 41743720)
32. Oliver, T.G. et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 24, 837-852 (2010).
33. Herbst, R.S., Heymach, J.V. & Lippman, S.M. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
34. Santamaría, D. et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811-815 (2007). (Pubitemid 47266342)
35. Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249-262 (2001). (Pubitemid 32206493)
36. Ji, H. et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485-495 (2006). (Pubitemid 43832191)